Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE

项目摘要/摘要 通过这项申请，德克萨斯大学MD安德森癌症中心寻求资金更新 它的前列腺癌孢子。本申请是根据多名首席调查员计划(MPI)提交的 由首席调查员Christopher J.Logothetis博士和Timothy C.Thompson博士撰写，他们被公认为 在国际上，MD Anderson前列腺癌孢子为他们的前列腺癌研究创造了一个 为翻译研究提供稳定、动态的基础架构，以满足并成功解决特定问题 减少前列腺癌患者痛苦和死亡率方面的挑战。我们继续在我们的 进行新颖、创新的临床试验的能力，并相信我们的新研究项目 翻译研究团队将在临床实践中取得实质性进展和有意义的变化。在 目前的建议，我们将我们的翻译研究挑战和目标定义为：(1)定量定义 前列腺癌风险消除低风险前列腺癌过度治疗，(2)开发新的 克服去势耐药前列腺癌(CRPC)对可用药耐药性的治疗方法 治疗方法，以及(3)开发CRPC和治疗难治性疾病的新替代策略。我们 将通过识别和测试新的预测和预测来实现这些翻译研究目标 用于确定早期前列腺癌患者是否需要治疗的生物标记物 测试CRPC的新免疫疗法，开发和测试克服骨分泌的新方法- 介导骨转移对治疗的耐药性，并开发和测试诱导联合疗法 最大化DNA损伤反应-CRPC的靶向治疗。我们将通过4项研究来实现我们的目标 项目(包括1个人口科学研究项目)、3个支助核心(行政、生物统计和 生物信息学、生物质谱学和病理学)、动态发展研究计划和 有效的职业提升计划。我们乐观地认为，我们的研究努力将有助于 通过转化基础研究，降低这种毁灭性疾病的发病率、发病率和死亡率 将这些发现转化为临床实践。

PROJECT SUMMARY/ABSTRACT Through this application, The University of Texas MD Anderson Cancer Center seeks funding for renewal of its Prostate Cancer SPORE. This application is submitted under the Multiple Principal Investigator plan (MPI) by Principal Investigators Drs. Christopher J. Logothetis and Timothy C. Thompson, who are recognized internationally for their research in prostate cancer, The MD Anderson Prostate Cancer SPORE has created a stable and dynamic infrastructure for translational research to meet and successfully address specific challenges in reducing suffering and mortality rates for men with prostate cancer. We continue to build on our capacity to conduct novel, innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal, we define our translational research challenges and goals as (1) quantitative definition of prostate cancer risk to eliminate overtreatment of low-risk prostate cancer, (2) development of novel therapeutic approaches to overcoming resistance of castration-resistant prostate cancer (CRPC) to available therapies, and (3) development of novel alternative strategies for CRPC and treatment-refractory disease. We will achieve these translational research goals by identifying and testing novel predictive and prognostic biomarkers to determine the need for therapy in patients with early-stage prostate cancer, developing and testing novel immunotherapy for CRPC, developing and testing a novel approach to overcoming osteocrine- mediated resistance of bone metastasis to therapy, and developing and testing lead-in combination therapy to maximize DNA damage response-targeted therapy for CRPC. We will accomplish our goals via 4 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Biospecimen and Pathology), a dynamic Developmental Research Program, and an effective Career Enhancement Program. We are optimistic that our research efforts will contribute to reductions in the incidence, morbidity, and mortality of this devastating disease by translating basic research findings into clinical practice.